These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35970070)

  • 1. Oxidized tea polyphenol (OTP-3) targets EGFR synergistic nimotuzumab at inhibition of non-small cell lung tumor growth.
    Huang Y; Cuan X; Yang X; Zhu W; Zhao Y; Jiang L; Zi C; Wang X; Sheng J
    Bioorg Chem; 2022 Nov; 128():106084. PubMed ID: 35970070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.
    Huang Y; Cuan X; Zhu W; Yang X; Zhao Y; Sheng J; Zi C; Wang X
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.
    Akashi Y; Okamoto I; Iwasa T; Yoshida T; Suzuki M; Hatashita E; Yamada Y; Satoh T; Fukuoka M; Ono K; Nakagawa K
    Br J Cancer; 2008 Feb; 98(4):749-55. PubMed ID: 18253126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.
    Yao N; Wang CR; Liu MQ; Li YJ; Chen WM; Li ZQ; Qi Q; Lu JJ; Fan CL; Chen MF; Qi M; Li XB; Hong J; Zhang DM; Ye WC
    Signal Transduct Target Ther; 2020 Oct; 5(1):214. PubMed ID: 33033232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer.
    Minnelli C; Cianfruglia L; Laudadio E; Mobbili G; Galeazzi R; Armeni T
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
    Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
    Berger C; Krengel U; Stang E; Moreno E; Madshus IH
    J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
    Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
    Pakkala S; Ramalingam SS
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
    Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
    Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
    Gridelli C; Maione P; Ferrara ML; Rossi A
    Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.